A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder

Journal of Clinical Psychiatry

Volumn 73, Issue 1, 2012, Pages 13-20

  Honer, William G ^a   MacEwan, G William ^a   Gendron, Alain ^b,c,d   Stip, Emmanuel ^c   Labelle, Alain ^e   Williams, Richard ^a   Eriksson, Hans ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d ASTRAZENECA   (United Kingdom)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLURAZEPAM; LORAZEPAM; PLACEBO; QUETIAPINE; ZALEPLON;

ADULT; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERSALIVATION; HYPOKINESIA; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TORTICOLLIS; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN;

EID: 84863014414     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06194     Document Type: Article

References (25)

1. Li C, Xia J, Wang J. Risperidone dose for schizophrenia. Cochrane Database Syst Rev. 2009;4(4):CD007474. PubMed
2. Citrome L, Kantrowitz JT. Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction? Expert Rev Neurother. 2009;9(7):1045-1058. doi:10.1586/ern.09.54 PubMed
3. Boggs DL, Kelly DL, Feldman S, et al. Quetiapine at high doses for the treatment of refractory schizophrenia. Schizophr Res. 2008;101(1-3): 347-348. doi:10.1016/j.schres.208.01.013
4. Pierre JM, Wirshing DA, Wirshing WC, et al. High-dose quetiapine in treatment refractory schizophrenia. Schizophr Res. 2005;73(2-3): 373-375. doi:10.1016/j.schres.204.07.014 PubMed (Pubitemid 40093903)
5. Citrome L, Jaffe A, Levine J, et al. Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J Clin Psychiatry. 2005;66(12):1512-1516. doi:10.408/JCP.v6n1203 PubMed (Pubitemid 43068688)
6. Emsley RA, Raniwalla J, Bailey PJ, et al; PRIZE Study Group. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol. 2000;15(3):121-131. doi:10.1097/04850-2015030-01 PubMed
7. Sparshatt A, Jones S, Taylor D. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs. 2008;22(1):49-68, discussion 69-72. doi:10.2165/023210-2082010-04 PubMed
8. Kahn RS, Schulz SC, Palazov VD, et al; Study 132 Investigators. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):832-842. doi:10.408/JCP.v68n0603 PubMed (Pubitemid 47015481)
9. Arvanitis LA, Miller BG. The Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry. 1997;42(4):233-246. doi:10.1016/S06-323(97)0190-X PubMed
10. Small JG, Hirsch SR, Arvanitis LA, et al; Seroquel Study Group. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry. 1997; 54(6):549-557. PubMed
11. Copolov DL, Link CGG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychol Med. 2000;30(1):95-105. doi:10.1017/S032917901476 PubMed (Pubitemid 30099122)
12. Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007; 46(5):359-388. doi:10.2165/0308-20746050-01 PubMed (Pubitemid 46686464)
13. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev. 2004;(2):CD000967. PubMed
14. Timdahl K, Carlsson A, Stening G. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms. Hum Psychopharmacol. 2007;22(5):315-325. doi:10.102/hup.853 PubMed (Pubitemid 47180393)
15. Brecher M, Leong RW, Stening G, et al. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry. 2007;68(4):597-603. doi:10.408/JCP.v68n0416 PubMed (Pubitemid 46663043)
16. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24(1):62-69. doi:10.1097/01.jcp.0104913.75206.62 PubMed (Pubitemid 38134167)
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
18. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. PubMed
19. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, & Welfare publication (ADM) 76-338). Rockville, MD: National Institute of Mental Health; 1976:218-222.
20. May PRA, Dencker SJ, Hubbard JW, et al. A systematic approach to treatment resistance in schizophrenic disorders. In: Dencker SJ, Kulhanek F, eds. Treatment Resistance in Schizophrenia. Vieweg. Braunschweig, Germany: Weisbaden; 1988:22-33.
21. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;212:11-19. PubMed
22. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154(5):672-676. doi:10.192/bjp.154.5.672 PubMed (Pubitemid 19154942)
23. Buckley PF, Goldstein JM, Emsley RA. Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophr Res. 2004; 66(2-3):143-150. doi:10.1016/j.schres.203.06.01 PubMed (Pubitemid 38041112)
24. Emsley RA, Buckley P, Jones AM, et al. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol. 2003;17(2):210-215. doi:10.17/0269810301702010 PubMed (Pubitemid 36753538)
25. Hunfeld NGM, Westerman EM, Boswijk DJ, et al. Quetiapine in overdosage: a clinical and pharmacokinetic analysis of 14 cases. Ther Drug Monit. 2006;28(2):185-189. (Pubitemid 44314947)